Presentation is loading. Please wait.

Presentation is loading. Please wait.

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Published byRudolf Hartmann Modified over 5 years ago

Similar presentations

Presentation on theme: "Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results."— Presentation transcript:

1 Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial  Robert Dufour, MD, MSc, CSPQ, G. Kees Hovingh, MD, PhD, MBA, John R. Guyton, MD, Gisle Langslet, MD, Marie T. Baccara-Dinet, MD, MSc, Chantal Din-Bell, MSc, Garen Manvelian, MD, Michel Farnier, MD, PhD  Journal of Clinical Lipidology  Volume 13, Issue 1, Pages (January 2019) DOI: /j.jacl Copyright © 2018 National Lipid Association Terms and Conditions

2 Figure 1 OLE study design. aPatients receiving placebo were part of the OLE study but were not included in this analysis. bPosttreatment follow-up call to be performed 10 weeks after the last injection. HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; OLE, open-label extension; Q2W, every 2 weeks; TLC, therapeutic lifestyle changes; W, week. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

3 Figure 2 Percent LDL-C change from baseline to Week 8 in the LONG TERM parent study and the OLE study, in the same cohort of HeFH patients (mITT analysis)a. aOnly patients who have all 4 LDL-C measurements (parent study baseline, OLE baseline, Week 8 parent study, and Week 8 OLE study) are included in this analysis. bResults for patient cohort during the LONG TERM study (n = 179). cResults for patient cohort during the OLE study (n = 179). LDL-C, low-density lipoprotein cholesterol; Q2W, every 2 weeks; mITT, modified intent-to-treat; SD, standard deviation; SE, standard error. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

4 Figure 3 Percent change in (A) HDL-C, (B) non-HDL-C, (C) TC, and (D) TGs from baseline to Week 8 in the LONG TERM parent study and OLE study, in the same cohort of HeFH patients (mITT analysis). Patient numbers for each lipid parameter are as follows: HDL-C, non-HDL-C, and TC, n = 185; TGs, and n = 182 respectively. aResults for patient cohort during the LONG TERM study. bResults for patient cohort during the OLE study. HDL-C, high-density lipoprotein cholesterol; mITT, modified intention-to-treat; Q2W, every 2 weeks; SD, standard deviation; SE, standard error; TC, total cholesterol; TGs, triglycerides. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

5 Figure 4 Mean (SD) LDL-C levels over time according to alirocumab dose increase status in OLE (mITT analysis). LDL-C, low-density lipoprotein cholesterol; mITT, modified intention-to-treat; Q2W, every 2 weeks; SD, standard deviation. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

Download ppt "Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results."

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,
ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:
% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline
ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

Similar presentations

Ads by Google